Skip to main content
Fig. 4 | Journal of Ovarian Research

Fig. 4

From: MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A

Fig. 4

miR-149-3p targeted TIMP2 and CDKN1A. A. Target genes of miR-149-3p was predicted. B. The expression of TIMP2 and CDKN1A in OC TCGA datasets. C The expression of TIMP2 and CDKN1A in cases with metastasis (n = 15) or without metastasis (n = 10). D. The expression of TIMP2 and CDKN1A in chemosensitive and chemoresistant OC tissues (n = 15). E. Correlation between miR-149-3p expression and TIMP2/CDKN1A expression was determined by Pearson correlation. F. q-PCR and Western blot were used to detect the expression of TIMP2 and CDKN1A in cells transfected with miR-149-3p inhibitor or mimic. G. The luciferase activities in A2780/DDP cells and SKOV3/DDP cells co-transfected wild-type (WT) or mutant (Mut) CDKN1A plasmid together with miR-149-3p mimic or NC mimic. H. The luciferase activities in A2780/DDP cells and SKOV3/DDP cells co-transfected wild-type (WT) or mutant (Mut) TIMP2 plasmid together with miR-149-3p mimic or NC mimic I-J. Ago2-RIP assay was used to detect the enrichment of TIMP2 and CDKN1A. *P < 0.05. All experiments were repeated three times with similar results

Back to article page